Comparative Pharmacology
Head-to-head clinical analysis: HALAVEN versus NELARABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALAVEN versus NELARABINE.
HALAVEN vs NELARABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Halaven (eribulin mesylate) is a microtubule dynamics inhibitor. It binds to tubulin, suppressing microtubule growth and sequestering tubulin into nonfunctional aggregates, leading to G2/M cell cycle arrest and apoptosis.
Nelarabine is a prodrug of ara-G, a deoxyguanosine analog. It is converted to ara-GTP, which accumulates in T-cells and inhibits DNA synthesis, leading to cell death.
1.4 mg/m2 intravenously over 2-5 minutes on days 1 and 8 of a 21-day cycle.
1500 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
None Documented
None Documented
Terminal elimination half-life approximately 30-50 hours (mean 40 hours). Clinically, this supports weekly dosing schedule.
Clinical Note
moderateNelarabine + Digoxin
"Nelarabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateNelarabine + Digitoxin
"Nelarabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateNelarabine + Deslanoside
"Nelarabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateNelarabine + Acetyldigitoxin
"Nelarabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal t1/2: 30 hours (range 21-48 h) in adults; prolonged in renal impairment. Ara-G (active metabolite) t1/2: 3 hours.
Primarily biliary/fecal: ~70-80% as unchanged drug and metabolites in feces; renal excretion accounts for <10% (mostly metabolites).
Renal: 50-60% as unchanged ara-G; fecal: <5% as metabolites; biliary: negligible.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent